Antirsesorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial
Authors:
- Edward G. LufkinELEdward G. Lufkin
- Leo PlouffeLPLeo Plouffe
- 14 January 2004
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (3) , 351-357
Abstract
SUMMARYStandard pharmacological antiresorptive therapy for the prevention and/or treatment of postmenopausal osteoporosis now consists of four categories of drugs: estrogens, a selective estrogen receptor modulator (SERM), bisphosponates, and calcitonin. All of these drugs have been studied in randomized controlled trials, but meaningful comparisons of the efficacy of drugs have been difficult due to differences in baseline risks for fracture and differences in study design, including calcium and vitamin D supplementation, definition of fracture, and discontinuation rates. The current paper reviews results from pivotal studies of antiresorptive therapies with fracture as a primary endpoint, as well as head-to-head trials comparing these therapies using surrogate markers of fracture risk, and introduces the first head-to-head trial with fracture as a primary endpoint. The Evista Alendronate Comparison (EVA) trial, a multi-center, double-blind, double-dummy, randomized trial with two active treatment arms i...Keywords
This publication has 39 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene TherapyJournal of Bone and Mineral Research, 2002
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001
- The Role of Selective Estrogen Receptor Modulators in the Prevention and Treatment of OsteoporosisRheumatic Disease Clinics of North America, 2001
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Prevalence of low femoral bone density in older U.S. women from NHANES IIIJournal of Bone and Mineral Research, 1995
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993
- Contribution of vertebral deformities to chronic back pain and disabilityJournal of Bone and Mineral Research, 1992
- Involutional OsteoporosisNew England Journal of Medicine, 1986